Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291006 | 1.00 | DRD2 (0.44) | DRD2CYP3A4KCNH2KDM2BKDM4E | |
| SCHEMBL13660586 | 1.00 | DRD2 (0.44) | DRD2CYP3A4KCNH2KDM2BKDM4E | |
| SCHEMBL13663228 | 1.00 | DRD2 (0.44) | DRD2CYP3A4KCNH2KDM2BKDM4E | |
| SCHEMBL18703911 | 0.85 | DRD2 (0.50) | DRD2CYP3A4KCNH2KDM2BKDM4E | |
| SCHEMBL18703914 | 0.84 | SLC18A3 (0.51) | DRD2CYP3A4KCNH2KDM2BKDM4E | |
| SCHEMBL7023905 | 0.82 | HRH3 (0.39) | CYP3A4KCNH2ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL13660519 | 0.80 | SLC18A3 (0.57) | CYP2D6CYP2C19 | |
| SCHEMBL13663364 | 0.77 | HRH3 (0.70) | CYP3A4KCNH2 | |
| SCHEMBL13660589 | 0.77 | HRH3 (0.70) | CYP3A4KCNH2 | |
| SCHEMBL13660588 | 0.77 | HRH3 (0.70) | CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | DRD2 188/4885CYP3A4 439/4885KCNH2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.